Pharmena SA
WSE:PHR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (8.8), the stock would be worth zł-3.12 (192% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -9.6 | zł3.39 |
0%
|
| Industry Average | 8.8 | zł-3.12 |
-192%
|
| Country Average | 11.3 | zł-3.97 |
-217%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| PL |
P
|
Pharmena SA
WSE:PHR
|
37.8m PLN | -9.6 | -18.9 | |
| FR |
|
L'Oreal SA
PAR:OR
|
200.6B EUR | 22.3 | 32.6 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
92.3B GBP | 12.9 | 11.3 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR | 40 | 37.6 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.3B GBP | 15 | 18.7 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
27.6B USD | 22.7 | -155.2 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
16B EUR | 9.8 | 16.9 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 14.8 | 22.2 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR | 42.2 | 64.1 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -6 360.4 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
815.9B INR | 38.9 | 43.3 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 8.1 |
| Median | 11.3 |
| 70th Percentile | 16 |
| Max | 313.7 |
Other Multiples
Pharmena SA
Glance View
PHARMENA SA engages in developing and marketing products based on a patented, physiological, and natural active substance 1-MNA. The company is headquartered in Lodz, Woj. Lodzkie and currently employs 24 full-time employees. The company went IPO on 2008-08-25. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
